Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Receivables: 2012-2025

Historic Change in Receivables for Ani Pharmaceuticals (ANIP) over the last 13 years, with Sep 2025 value amounting to $27.0 million.

  • Ani Pharmaceuticals' Change in Receivables rose 419.57% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.2 million, marking a year-over-year increase of 365.17%. This contributed to the annual value of $21.1 million for FY2024, which is 727.78% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Change in Receivables of $27.0 million as of Q3 2025, which was up 391.08% from $5.5 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Change in Receivables high stood at $27.0 million for Q3 2025, and its period low was -$16.8 million during Q4 2023.
  • Its 3-year average for Change in Receivables is $4.4 million, with a median of $5.5 million in 2025.
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 2,333.29% in 2022, then tumbled by 253.66% in 2024.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Change in Receivables stood at -$5.4 million in 2021, then skyrocketed by 565.38% to $25.0 million in 2022, then tumbled by 167.04% to -$16.8 million in 2023, then spiked by 252.20% to $25.5 million in 2024, then surged by 419.57% to $27.0 million in 2025.
  • Its Change in Receivables stands at $27.0 million for Q3 2025, versus $5.5 million for Q2 2025 and -$1.8 million for Q1 2025.